Voyageur Pharmaceuticals Ltd.
VYYRF
$0.1285
$0.000.00%
OTC PK
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.71% | 115.66% | 78.61% | 179.73% | -12.07% |
| Depreciation & Amortization | -33.33% | -33.33% | -25.00% | -25.00% | -25.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.71% | 115.46% | 78.36% | 178.74% | -12.08% |
| Operating Income | 28.71% | -115.46% | -78.36% | -178.74% | 12.08% |
| Income Before Tax | 6.11% | -133.37% | -61.17% | -167.28% | 9.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.11% | -133.37% | -61.17% | -167.28% | 9.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.11% | -133.37% | -61.17% | -167.28% | 9.98% |
| EBIT | 28.71% | -115.46% | -78.36% | -178.74% | 12.08% |
| EBITDA | 28.71% | -115.66% | -78.61% | -179.73% | 12.07% |
| EPS Basic | 20.00% | -105.56% | -50.00% | -171.43% | 14.29% |
| Normalized Basic EPS | 21.05% | -91.67% | -87.50% | -140.00% | 13.64% |
| EPS Diluted | 20.00% | -105.56% | -50.00% | -171.43% | 14.29% |
| Normalized Diluted EPS | 21.05% | -91.67% | -87.50% | -140.00% | 13.64% |
| Average Basic Shares Outstanding | 16.05% | 17.16% | 5.05% | 5.08% | 4.66% |
| Average Diluted Shares Outstanding | 16.05% | 17.16% | 5.05% | 5.08% | 4.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |